XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)
$ in Millions
3 Months Ended
Apr. 02, 2023
Apr. 03, 2022
Restructuring charges/(credits):    
Employee terminations $ (36) $ 25
Asset impairments (10) 8
Exit costs/(credits) 2 11
Restructuring charges/(credits) [1] (44) 43
Transaction costs [2] 0 6
Integration costs and other [3] 52 142
Restructuring charges and certain acquisition-related costs 9 192
Implementation costs [4] 85 85
Total costs associated with acquisitions and cost-reduction/productivity initiatives 107 280
Biopharma [Member]    
Restructuring charges/(credits):    
Restructuring charges/(credits) (28) (4)
Other (income)/deductions––net [Member]    
Restructuring charges/(credits):    
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net (5) (6)
Cost of sales [Member]    
Restructuring charges/(credits):    
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income, mainly in Cost of sales [5] 18 9
Implementation costs [4] 15 12
Selling, informational and administrative expenses [Member]    
Restructuring charges/(credits):    
Implementation costs [4] 59 74
Research and Development Expense [Member]    
Restructuring charges/(credits):    
Implementation costs [4] $ 11 0
Restructuring Charges And Acquisition-Related Costs [Member] | Arena [Member]    
Restructuring charges/(credits):    
Post closing compensation expense   $ 138
[1] Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: credits of $28 million for the three months ended April 2, 2023 and credits of $4 million for the three months ended April 3, 2022.
[2] Represents external costs for banking, legal, accounting and other similar services.
[3] Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the first quarter of 2022, integration costs and other were mostly related to our acquisition of Arena, including $138 million in payments to Arena employees for the fair value of previously unvested long-term incentive awards that was recognized as post-closing compensation expense.
[4] Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
[5] Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.